Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
MANA Therapeutics Launches with $35 Million Series A Financing
Details : MANA is using its EDIFY™ platform to develop a pipeline of proprietary and partnered off-the-shelf cell therapies for cancer patients across a broad range of liquid and solid tumors, with an initial focus on relapsed acute myeloid leukemia.
Product Name : MANA-312
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
August 01, 2021